Macrolux, a leading medical technology company specializing in disposable endoscopes, has announced the completion of a Series B financing round exceeding RMB 100 million (over USD 14.75 million). The round was led by BioVenture VC, with continued support from existing investors Legend Capital and DALTON VENTURE, and HAOYUE CAPITAL serving as the exclusive financial advisor. This funding will accelerate Macrolux’s capacity expansion, new product development, and global market reach, driving its rapid growth in the disposable endoscope sector.
Use of Proceeds
The funds raised will be used to further expand Macrolux’s production capacity, accelerate the development of new products, and enhance its global market presence. This strategic investment aims to solidify Macrolux’s position as an innovation leader in disposable endoscopes, addressing the growing demand for high-quality, single-use medical devices.
Company Background and Core Products
Founded in October 2020, Macrolux is led by a team with over a decade of experience in minimally invasive surgical device R&D, global marketing, and production management. The company’s core product, the disposable electronic endoscope, covers a range of medical specialties including urology, respiratory, ICU, gynecology, and gastroenterology. Macrolux’s products are already marketed in China, the US, Europe, and the Asia-Pacific region, highlighting its commitment to global healthcare innovation.-Fineline Info & Tech
